Abstract |
We have measured the serum levels of soluble CD4, CD8 and IL-2R in 43 patients with AML in complete remission (AML-CR). The sCD8 levels of AML-CR patients (443.9 +/- 224.4 u/ml) were significantly high as compared to that of the normal controls (177.1 +/- 76.3 u/ml), p < 0.01. The sIL-2R levels of AML-CR patients were 715.0 +/- 646.3 u/ml, which significantly differed when compared to 322.1 +/- 65.7 u/ml for the normal controls, p < 0.01. However, the sCD4 levels of AML-CR patients were 9.6 +/- 4.7 u/ml, which did not differ from the 8.3 +/- 2.6 u/ml of the normal controls. The AML-CR patients showed significantly increased sCD8 and sIL-2R levels at all ranges during the remission from one to 188 months. The sCD8 levels and sIL-2R levels of the AML-CR patients showed a close correlation, p < 0.01. Further, the sCD8 levels and lymphokine activated killer cell cytotoxic activity showed a close correlation, p < 0.05. The presence of the activation of anti- tumor immunity may be related to the continuance of the remission in the AML-CR patients.
|
Authors | Y Iizuka, M Aiso, T Ohshima, S Sawada, T Horie |
Journal | Medical oncology and tumor pharmacotherapy
(Med Oncol Tumor Pharmacother)
Vol. 9
Issue 2
Pg. 57-64
( 1992)
ISSN: 0736-0118 [Print] England |
PMID | 1341717
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- CD4 Antigens
- CD8 Antigens
- Interleukin-2
- Cytarabine
- Prednisolone
- Mercaptopurine
- Daunorubicin
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers
(blood)
- CD4 Antigens
(blood)
- CD8 Antigens
(blood)
- Cytarabine
(therapeutic use)
- Cytotoxicity, Immunologic
(immunology)
- Daunorubicin
(therapeutic use)
- Female
- Humans
- Immunophenotyping
- Interleukin-2
(blood)
- Killer Cells, Lymphokine-Activated
(immunology)
- Killer Cells, Natural
(immunology)
- Leukemia, Myeloid
(drug therapy, immunology)
- Male
- Mercaptopurine
(therapeutic use)
- Middle Aged
- Prednisolone
(therapeutic use)
- Remission Induction
|